


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.10%
-4.04%
+0.72%
-1.07%
-1.32%
HALO
Halozyme Therapeutic
$69.87
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market
HALO Price Performance
$68.87 (+1.45%)
$65.26 (+7.06%)
$73.34 (-4.73%)
$57.34 (+21.85%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
HALO Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HALO Street Sentiment is extremely bullish and have positive views on the near-term outlook
HALO has Low risk level

Average key support and resistance price levels
What is HALO current stock price?
What are HALO stock strengths?
What is HALO Risk Level?
What is HALO market cap and volume?
What is HALO current Stock IQ?
Should I buy HALO stock right now?
Is HALO a Strong Buy right now?
What does a 'Strong Buy' rating mean for HALO?
What does a 'Strong Sell' rating mean for HALO?
What factors influence HALO's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.10%
-4.04%
+0.72%
-1.07%
-1.32%
HALO
Halozyme Therapeutic
Current Price
$69.87
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

HALO Price Performance
$68.87 (+1.45%)
$65.26 (+7.06%)
$73.34 (-4.73%)
$57.34 (+21.85%)
HALO Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
HALO Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HALO Street Sentiment is extremely bullish and have positive views on the near-term outlook
HALO has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 20, 2026
Upgrade
Buy
TD Cowen
Nov 29, 2025
Reiterate
Buy
HC Wainwright & Co.
Nov 05, 2025
Reiterate
Outperform
Citizens
Oct 28, 2025
Reiterate
Buy
H.C. Wainwright
Oct 15, 2025
Upgrade
Market
Leerink
Oct 15, 2025
Reiterate
Buy
HC Wainwright & Co.
HALO Stock IQ
HALO Latest Analysis
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings 2026 Guidance. Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the best mid-cap growth stocks to buy right now. On January 8 TD Cowen raised its price target on Halozyme to $90 from $79 and kept a Buy rating. Ahead of Q4 2025 earnings the firm adjusted price targets within the diagnostic tools group and noted that investor [….]
Fri Jan 23, 2026
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty. Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!.Stock prices used were t
Tue Jan 20, 2026
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade. Halozyme Therapeutics Inc. (NASDAQ:HALO) ranks among the 10 best new stocks to buy in Ray Dalios portfolio. On January 8 TD Cowen boosted Halozyme Therapeutics Inc. (NASDAQ:HALO) price target from $79 to $90 while maintaining a Buy rating on the companys shares. The firm stated that Halozyme Therapeutics Inc. (NASDAQ:HALO) is expected to enhance its [….]
Tue Jan 20, 2026
Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tue Jan 13, 2026
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab . (RTTNews) - Halozyme Therapeutics Inc. (HALO) Thursday announced that the company has entered a global collaboration and exclusive license agreement with Takeda allowing the latter to access ENHANZE drug delivery technology for use with vedolizumab.
Thu Jan 8, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
HALO Stock trends
HALO Stock performance
HALO Stock analysis
HALO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.